Avigen
Biotechnology ResearchUnited States11-50 Employees
Learn about working at Avigen. Join LinkedIn today for free. See who you know at Avigen, leverage your professional network, and get hired.
Niche Asset Sale Avigen recently divested its AAV assets to MediciNova, indicating a strategic focus shift. This suggests potential opportunities to collaborate on or leverage related biotech assets and technologies in similar or complementary markets.
Financial Growth Potential With annual revenues between $10M and $25M and a specialized biotech focus, Avigen offers a growth-oriented partnership prospect, especially as its assets may understate its upside potential following recent asset sales.
Leadership Transition The retirement of Avigen’s CEO in August 2021 may signal upcoming leadership changes, opening doors for engaging with new decision-makers and strategic partners during leadership onboarding or company restructuring.
Innovative Technologies By selling its AAV assets and focusing on biotech R&D, Avigen is positioned in a promising segment of gene therapy and vector development, presenting opportunities for companies interested in advanced biotechnology collaborations.
Market Positioning Compared to larger biotech firms, Avigen’s smaller size and focused asset portfolio offer opportunities to develop tailored, high-value solutions and strategic alliances in niche biotech markets.
Avigen uses 1 technology products and services including GoDaddy, and more. Explore Avigen's tech stack below.
| Avigen Email Formats | Percentage |
| FLast@avigen.com | 50% |
| FLast@avigen.com | 50% |
Biotechnology ResearchUnited States11-50 Employees
Learn about working at Avigen. Join LinkedIn today for free. See who you know at Avigen, leverage your professional network, and get hired.
Avigen's revenue is estimated to be in the range of $10M$25M
Avigen's revenue is estimated to be in the range of $10M$25M